Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Finch Therapeutics Group Inc FNCH

Healthcare Biotechnology
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U... see more

Recent & Breaking News (PINL:FNCH)

Finch Announces Delisting from Nasdaq and SEC Deregistration

GlobeNewswire October 21, 2024

Finch Announces Reverse Stock Split of Common Stock

GlobeNewswire June 9, 2023

Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire May 10, 2023

Finch Therapeutics Announces Executive Leadership Transitions

GlobeNewswire April 25, 2023

Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement

GlobeNewswire April 18, 2023

Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

GlobeNewswire March 23, 2023

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

GlobeNewswire January 24, 2023

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 10, 2022

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

GlobeNewswire November 9, 2022

Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection

GlobeNewswire October 24, 2022

Finch Therapeutics Provides Business Update

GlobeNewswire September 1, 2022

Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD

GlobeNewswire August 25, 2022

Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 11, 2022

Finch Therapeutics to Participate in Upcoming June Investor Conferences

GlobeNewswire June 2, 2022

Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 16, 2022

Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

GlobeNewswire May 9, 2022

Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND

GlobeNewswire April 28, 2022

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

GlobeNewswire April 19, 2022

Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

GlobeNewswire March 31, 2022